DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report released on Monday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities reissued a "market outperform" rating and set a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Up 1.8 %

DBV Technologies stock traded up $0.13 during mid-day trading on Monday, reaching $7.32. 39,437 shares of the company's stock were exchanged, compared to its average volume of 178,864. The company has a fifty day moving average of $5.10 and a 200-day moving average of $4.14. The company has a market cap of $150.57 million, a P/E ratio of -1.63 and a beta of -0.08. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $8.50.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. Equities research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.